title: ISAtx-247 (Isotechnika/Roche).
abstract: ISAtx-247 is a ciclosporin A analog under development by Isotechnika and Roche as an immunosuppressant for the potential prevention of organ rejection after transplantation, and for the potential treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis and type 1 diabetes. A phase II renal transplantation study had been completed by June 2003.
authors.affiliation: Medor Consulting, 421 Dogwood Avenue, Egg Harbor Twp, NJ 08234, USA. francisj_dumont@yahoo.com
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Dumont
mesh_terms: D000818:Animals; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000517:prevention & control; D065095:Calcineurin Inhibitors; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D011565:Psoriasis / Q000188:drug therapy; D013329:Structure-Activity Relationship
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; C484071:voclosporin; D016572:Cyclosporine